Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs
Verma R, Mai Z, Xu M, Zhang L, Dhodapkar K, Dhodapkar M. Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs. Blood 2015, 126: 913. DOI: 10.1182/blood.v126.23.913.913.Peer-Reviewed Original ResearchResidual MM cellsDegradation of IKZF1MM cellsClonogenic growthRNAi-mediated inhibitionHDAC inhibitorsMyeloma cellsResidual myeloma cellsSynergistic anti-tumor effectImmune-modulatory drugsHuman MM cellsPrimary MM cellsAnti-myeloma effectTrichostatin AMM plasma cellsAnti-tumor effectsMM cell linesAnti-proliferative effectsConcurrent therapyImmunomodulatory drugsResidual diseaseModulatory drugsPlasma cellsT cellsRecent studiesRussell body duodenitis with immunoglobulin kappa light chain restriction
Munday WR, Kapur LH, Xu M, Zhang X. Russell body duodenitis with immunoglobulin kappa light chain restriction. World Journal Of Gastrointestinal Endoscopy 2015, 7: 73-76. PMID: 25610537, PMCID: PMC4295184, DOI: 10.4253/wjge.v7.i1.73.Peer-Reviewed Original ResearchRussell body duodenitisLight chain restrictionChain restrictionKappa light chain restrictionImmunoglobulin light chain restrictionEosinophilic intracytoplasmic globulesRussell body gastritisBody gastritisDisturbed secretionPeptic duodenitisIntracytoplasmic globulesCase reportPlasma cellsDuodenitisSimilar lesionsHelicobacter pyloriRussell bodiesFirst case